02 October 2026
: Case report
[In Press] Life-Threatening Pancytopenia and Disseminated Intravascular Coagulation Associated With Hydralazine-Induced Lupus and Vasculitis Overlap: A Comprehensive Case Report
Unusual clinical course, Challenging differential diagnosis, Unusual setting of medical care, Rare coexistence of disease or pathology
Yangming CaoDOI: 10.12659/AJCR.954113
Am J Case Rep In Press; DOI: 10.12659/AJCR.954113
Available online: 2026-10-02, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
This report presents a life-threatening case of pancytopenia and disseminated intravascular coagulation (DIC) related to hydralazine-associated, drug-induced lupus and drug-induced anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (DIL/DIV) overlap syndrome. Diagnostic and therapeutic challenges are discussed.
CASE REPORT
A 52-year-old man presented with severe pancytopenia, fever, and possible pneumonia. He developed altered mental status, severe DIC with gastrointestinal bleeds requiring large amount of blood product transfusions, acute respiratory failure requiring intubation, acute kidney injury needing hemodialysis, acute liver injury, possible acute pancreatitis, and hypotension. Extensive investigations revealed no source of infection. Further workup was consistent with hydralazine-induced DIL/DIV overlap spectrum. Hydralazine was stopped. He was treated with steroids daily and intravenous cyclophosphamide every 2 weeks (7 doses). However, pancytopenia did not improve. Therefore, on the seventh day after the second cyclophosphamide dose, a repeat bone marrow biopsy was performed to guide further therapy. He later recovered, and hemodialysis was discontinued. A total of 104 units of blood products were transfused. After discharge, steroids were tapered off and mycophenolate mofetil was given for 2 years. In August 2026 (6 years after initial presentation), he was doing well, with normal complete blood count, stable renal function, and normal urinalysis. Array genotyping revealed NAT2 diplotype *5.002/*6.002, indicating slow acetylation (poor metabolizer status).
CONCLUSIONS
This case supports, rather than proves, hydralazine-induced DIL/DIV overlap as the leading explanation for life-threatening pancytopenia with overt DIC. It highlights diagnostic and therapeutic challenges and eventual recovery after hydralazine withdrawal and immunosuppressive treatment. Salient features include the detailed autoimmune workup, severe presentation, coexistence of pancytopenia and overt DIC, and extended follow-up within a rare clinical context.
Keywords: Disseminated Intravascular Coagulation; Hydralazine; Lupus Erythematosus, Systemic; Pancytopenia; Vasculitis
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953196
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954118
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954366
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953858
Most Viewed Current Articles
07 Dec 2021 : Case report
27,881,002
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
180,132
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
123,851
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
08 May 2026 : Case report
93,868
DOI :10.12659/AJCR.952158
Am J Case Rep 2026; 27:e952158






